Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: Results of a 2-year, double-blind, placebo-controlled, crossover study

Multiple Sclerosis

Volumn 15, Issue 6, 2009, Pages 767-770

  Stelmasiak, Z ^a   Solski, J ^a   Nowicki, J ^a   Jakubowska, B ^a   Ryba, M ^b   Grieb, P ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Cladribine; Disease modifying therapies; Multiple sclerosis; Outcome measurement; Relapsing

Indexed keywords

ANTIBIOTIC AGENT; CLADRIBINE; CORTICOSTEROID DERIVATIVE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SIDE EFFECT; THROMBOCYTE COUNT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; CLADRIBINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLACEBOS; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66149179141     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509103610     Document Type: Article

References (9)

1. Leist, T, Vermersch, P. The potential role for cladribine in the treatment of multiple sclerosis: Clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007; 23: 2667-2676.
2. Beutler, E, Sipe, JC, Romine, JS, Koziol, J, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A 1996; 93: 1716-1720.
3. Rice, GP, Filippi, M, Comi, G. Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54: 1145-1155.
4. Romine, JS, Sipe, JC, Kozioi, JA, Zyroff, J, Beutler, E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians 1999; 111: 35-44.
5. Stelmasiak, Z, Solski, J, Nowicki, J. A pilot trial of cladribine (2-chlorodeoxyadenosine) in remitting-relapsing multiple sclerosis. Med Sci Monit 1998; 4: 4-8.
6. Cook, SD, et al. for the Cladribine Clinical Study Group. Combined analysis of the safety and tolerability of cladribine from four randomized, double-blind, parallel-group, placebo-controlled trials in patients with multiple sclerosis. In: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 12th Annual Conference of Rehabilitation in MS (RIMS). Prague, Czech Republic: 2007.
7. Brown, MG, Kirby, S, Skedgel, C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS ? Neurology 2007; 69: 1498-1507.
8. Martinez-Yelamos, S, Martinez-Yelamos, A, Martin, Ozaeta, G, Casado Carmona, O, Arbizu, T. Regression to the mean in multiple sclerosis. Mult Scler 2006; 12: 826-829.
9. Armitage, P. Should we cross off the crossover. Br J Clin Pharmacol 1991; 32: 1-2.